S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NYSE:CTLT

Catalent Stock Forecast, Price & News

$104.55
+1.47 (+1.43 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$97.86
Now: $104.55
$105.10
50-Day Range
$103.08
MA: $116.23
$125.27
52-Week Range
$31.04
Now: $104.55
$127.68
Volume1.30 million shs
Average Volume1.02 million shs
Market Capitalization$17.80 billion
P/E Ratio66.59
Dividend YieldN/A
Beta1.5
Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has a collaboration with the Janssen Pharmaceutical Companies; Arcturus Therapeutics Holdings Inc.; and BrainStorm Cell Therapeutics Inc. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Catalent logo

Headlines

Form 8-K Catalent, Inc. For: Feb 10 - StreetInsider.com
February 10, 2021 |  streetinsider.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone732-537-6200
Employees14,000
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.09 billion
Cash Flow$3.39 per share
Book Value$18.71 per share

Profitability

Net Income$173 million

Miscellaneous

Market Cap$17.80 billion
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.88 out of 5 stars

Medical Sector

122nd out of 1,972 stocks

Pharmaceutical Preparations Industry

49th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$104.55
+1.47 (+1.43 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CTLT News and Ratings via Email

Sign-up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Catalent (NYSE:CTLT) Frequently Asked Questions

Is Catalent a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Catalent stock.
View analyst ratings for Catalent
or view top-rated stocks.

What stocks does MarketBeat like better than Catalent?

Wall Street analysts have given Catalent a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Catalent wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Catalent's next earnings date?

Catalent is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Catalent
.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) issued its earnings results on Monday, February, 1st. The company reported $0.63 EPS for the quarter, beating the Zacks' consensus estimate of $0.55 by $0.08. The business earned $910.80 million during the quarter, compared to analyst estimates of $893.68 million. Catalent had a net margin of 9.25% and a trailing twelve-month return on equity of 14.20%. The company's quarterly revenue was up 26.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.45 EPS.
View Catalent's earnings history
.

How has Catalent's stock price been impacted by COVID-19?

Catalent's stock was trading at $46.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CTLT shares have increased by 127.0% and is now trading at $104.55.
View which stocks have been most impacted by COVID-19
.

What guidance has Catalent issued on next quarter's earnings?

Catalent updated its FY 2021 Pre-Market earnings guidance on Tuesday, February, 2nd. The company provided earnings per share (EPS) guidance of 2.64-2.88 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.56. The company issued revenue guidance of $3.8-3.95 billion, compared to the consensus revenue estimate of $3.73 billion.

What price target have analysts set for CTLT?

8 Wall Street analysts have issued 12 month price objectives for Catalent's shares. Their forecasts range from $100.00 to $140.00. On average, they anticipate Catalent's share price to reach $125.13 in the next year. This suggests a possible upside of 19.7% from the stock's current price.
View analysts' price targets for Catalent
or view top-rated stocks among Wall Street analysts.

Who are Catalent's key executives?

Catalent's management team includes the following people:
  • Mr. John R. Chiminski, Chairman & CEO (Age 57, Pay $2.53M)
  • Mr. Alessandro Maselli, Pres & COO (Age 49, Pay $2.09M)
  • Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 49, Pay $988.4k)
  • Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 58, Pay $1.09M)
  • Ms. Karen A. Flynn, Pres of Biologics & Chief Commercial Officer (Age 58, Pay $665.37k)
  • Mr. Julien Meissonnier, VP & Chief Scientific Officer
  • Mr. Paul Surdez, VP of Investor Relations
  • Mr. Michael J. Grippo, Sr. VP of Strategy & Corp. Devel. (Age 52)
  • Mr. Ricardo Pravda, Sr. VP & Chief HR Officer (Age 50)
  • Dr. Aristippos Gennadios, Pres of Softgel & Oral Technologies (Age 55)

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent CEO John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among Catalent's employees.

Who are some of Catalent's key competitors?

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Who are Catalent's major shareholders?

Catalent's stock is owned by a variety of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (11.96%), BlackRock Inc. (8.07%), Janus Henderson Group PLC (7.02%), JPMorgan Chase & Co. (3.13%), Artisan Partners Limited Partnership (2.51%) and Northern Trust Corp (0.97%). Company insiders that own Catalent stock include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, Donald E Morel, Jr, Gregory T Lucier, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Lance Miyamoto, Michael J Grippo, Peter L Buzy, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Scott Gunther, Steven L Fasman and Wetteny Joseph.
View institutional ownership trends for Catalent
.

Which major investors are selling Catalent stock?

CTLT stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Schroder Investment Management Group, Schroder Investment Management Group, Price T Rowe Associates Inc. MD, Artisan Partners Limited Partnership, Dimensional Fund Advisors LP, Public Employees Retirement Association of Colorado, and Clearbridge Investments LLC. Company insiders that have sold Catalent company stock in the last year include Alessandro Maselli, Aristippos Gennadios, Gregory T Lucier, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Michael J Grippo, Peter Zippelius, Ricci S Whitlow, Scott Gunther, Steven L Fasman, and Wetteny Joseph.
View insider buying and selling activity for Catalent
or view top insider-selling stocks.

Which major investors are buying Catalent stock?

CTLT stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, AGF Investments Inc., Assenagon Asset Management S.A., Thornburg Investment Management Inc., First Trust Advisors LP, The Manufacturers Life Insurance Company , BlackRock Inc., and Morgan Stanley. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, Gregory T Lucier, and Peter L Buzy.
View insider buying and selling activity for Catalent
or or view top insider-buying stocks.

How do I buy shares of Catalent?

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $104.55.

How much money does Catalent make?

Catalent has a market capitalization of $17.80 billion and generates $3.09 billion in revenue each year. The company earns $173 million in net income (profit) each year or $1.88 on an earnings per share basis.

How many employees does Catalent have?

Catalent employs 14,000 workers across the globe.

What is Catalent's official website?

The official website for Catalent is www.catalent.com.

Where are Catalent's headquarters?

Catalent is headquartered at 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.